ArticleOncotarget2014
Sp1-mediated microRNA-182 expression regulates lung cancer progression.
Article in Oncotarget, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 58 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
58 citing papers in PubMed, 1 synthesis or guideline pooled it, 78 citations in OpenAlex.
- Prognostic Value of MicroRNA-182 in Cancers: A Meta-Analysis.Disease markers · 2015Pooled it
- A novel approach in the identification of microRNAs in malignant pleural effusion for lung cancer diagnosis.Oncology reviews · 2025Review
- Discovering the role of microRNAs and exosomal microRNAs in chest and pulmonary diseases: a spotlight on chronic obstructive pulmonary disease.Molecular genetics and genomics : MGG · 2024Review
- Microglial Sp1 induced LRRK2 upregulation in response to manganese exposure, and 17β-estradiol afforded protection against this manganese toxicity.Neurotoxicology · 2024Article
- Bioinformatics Study and Experimental Evaluation of miR-182, and miR-34 Expression Profiles in Tuberculosis and Lung Cancer.Tuberculosis and respiratory diseases · 2024Article
- The Role of Autophagy in Human Uveal Melanoma and the Development of Potential Disease Biomarkers and Novel Therapeutic Paradigms.Biomedicines · 2024Review
- Article
- The emerging role of MicroRNA-182 in tumorigenesis; a promising therapeutic target.Cancer cell international · 2023Review
- MicroRNA-183 cluster: a promising biomarker and therapeutic target in gastrointestinal malignancies.American journal of cancer research · 2023Review
- Estradiol-mediated inhibition of Sp1 decreases miR-3194-5p expression to enhance CD44 expression during lung cancer progression.Journal of biomedical science · 2022Article
- The role of non-coding RNAs in chemotherapy for gastrointestinal cancers.Molecular therapy. Nucleic acids · 2021Review
- Histone deacetylase 6 acts upstream of DNA damage response activation to support the survival of glioblastoma cells.Cell death & disease · 2021Article
- Clinical Significance of miR-183-3p and miR-182-5p in NSCLC and Their Correlation.Cancer management and research · 2021Article
- MiR-182-5p promotes the Metastasis and Epithelial-mesenchymal Transition in Non-small Cell Lung Cancer by Targeting EPAS1.Journal of Cancer · 2021Article
- Comprehensive network analysis of different subtypes of molecular disorders in lung cancer.American journal of translational research · 2021Article
- miR-182 modulates cell proliferation and invasion in prostate cancer via targeting ST6GALNAC5.Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologica · 2021Article
- Dual roles of chromatin remodeling protein BRG1 in angiotensin II-induced endothelial-mesenchymal transition.Cell death & disease · 2020Article
- Sp1 in Astrocyte Is Important for Neurite Outgrowth and Synaptogenesis.Molecular neurobiology · 2020Article
- Chasing the FOXO3: Insights into Its New Mitochondrial Lair in Colorectal Cancer Landscape.Cancers · 2019Review
- MicroRNA-144 attenuates cardiac ischemia/reperfusion injury by targeting FOXO1.Experimental and therapeutic medicine · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Our recent study indicated that overexpression of Sp1 enhances the proliferation of lung cancer cells, while represses metastasis. In this study, we found that the transcriptional activity of FOXO3 was increased, but its protein levels decreased following Sp1 expression. Sp1 increased expression of miR-182, which was then recruited to the 3'-untranslated region of FOXO3 mRNA to silence its translational activity. Knockdown of miR-182 inhibited lung cancer cells growth, but enhanced the invasive and migratory abilities of these cells through increased N-cadherin expression. Repression of FOXO3 expression in the miR-182 knockdown cells partially reversed this effect, suggesting that miR-182 promotes cancer cell growth and inhibits cancer metastatic activity by regulating the expression of FOXO3. The expression of several cancer metastasis-related genes such as ADAM9, CDH9 and CD44 was increased following miR-182 knockdown. In conclusion, in the early stages of lung cancer progression, Sp1 stimulates miR-182 expression, which in turn decreases FOXO3 expression. This stimulates proliferation and tumor growth. In the late stages, Sp1 and miR-182 decline, thus increasing FOXO3 expression, which leads to lung metastasis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.